Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections Boston USA March 8-11, 2020 Back

Tweet

CROI ART/HIV Drug Studies       Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks - (03/09/20)   Potential Drugs for Multi-drug Resistant HIV NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV - (03/11/20)   Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/13/20)   RANDOMIZED SWITCH TO B/F/TAF IN AFRICAN AMERICAN ADULTS WITH HIV - (03/12/20)   144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years - (03/12/20)   DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 - (03/11/20)   LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20)   Use of D/C/F/TAF With Neurologic/Psychiatric Comorbidities: AMBER Subgroup Analysis (03/16/20)   Risks of metabolic syndrome, diabetes, and cardiovascular disease in ADVANCE trial. Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG - (03/12/20)   FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS (03/16/20)   CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (03/16/20)   DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (03/16/20)   ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS (03/16/20)   PK, Food Effect, and Safety of Oral GS-6207, a Novel HIV-1 Capsid Inhibitor (03/16/20)   Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)   100+ CROI NATAP Reports Conference on Retroviruses and Opportunistic Infections Boston USA March 8-11, 2020